STL Index for: Risankizumab

Psoriasis Education Tool for Patient-Physician Decision-Making About Biologics: A Pilot Study

Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.

Skin Treatments Introduced in 2020

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

2020 Index for Skin Therapy Letter – Dermatology Edition

This index covers all new skin treatments introduced in Skin Therapy Letter Dermatology Edition articles in 2020.

Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature

The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.

Skin Treatments Introduced in 2019

A variety of new skin treatments introduced in 2019.

Update on Drugs & Devices: May – June 2019

Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).

POPULAR